Showing results (1-10 of 323) with videos related to
Sort By:
Pageof 33
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|January 1, 2008
Modeling therapy resistance in genetically engineered mouse cancer modelsSven Rottenberg, Jos JonkersBreast Cancer Research : BCR|November 7, 2012
MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expressionSven Rottenberg, Jos JonkersCell Cycle (Georgetown, Tex.)|April 18, 2008
How do real tumors become resistant to cisplatin?Piet Borst, Sven Rottenberg, Jos JonkersMethods in Molecular Biology (Clifton, N.J.)|December 2, 2009
Studying drug resistance using genetically engineered mouse models for breast cancerSven Rottenberg, Marina Pajic, Jos JonkersCell Cycle (Georgetown, Tex.)|November 14, 2007
What makes tumors multidrug resistant?Piet Borst, Jos Jonkers, Sven RottenbergSTAR Protocols|February 11, 2022
Functional genetic dropout screens and <i>in vivo</i> validation of candidate therapeutic targets using mouse mammary tumoroidsMariana Paes Dias, Sven Rottenberg, Jos JonkersBiochimica Et Biophysica Acta|July 21, 2009
Therapeutic options for triple-negative breast cancers with defective homologous recombinationJanneke E Jaspers, Sven Rottenberg, Jos JonkersCold Spring Harbor Symposia on Quantitative Biology|November 6, 2016
Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast CancerStefano Annunziato, Marco Barazas, Sven Rottenberg, et al.Cell Cycle (Georgetown, Tex.)|September 22, 2010
Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivoMarina Pajic, Ariena Kersbergen, Frank van Diepen, et al.Plos One|October 3, 2012
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumorsSerge A L Zander, Wendy Sol, Lee Greenberger, et al.Pageof 33